Head-To-Head Survey: Jushi (OTCMKTS:JUSHF) vs. Evolus (NASDAQ:EOLS)

Jushi (OTCMKTS:JUSHF) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Earnings and Valuation

This table compares Jushi and Evolus”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jushi	$262.91 million	0.36	-$68.59 million	($0.36)	-1.32
Evolus	$297.18 million	1.49	-$51.64 million	($0.67)	-10.04

Evolus has higher revenue and earnings than Jushi. Evolus is trading at a lower price-to-earnings ratio than Jushi, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Jushi and Evolus, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jushi	0	0	1	0	3.00
Evolus	1	1	4	0	2.50

Evolus has a consensus price target of $16.00, indicating a potential upside of 137.74%. Given Evolus’ higher probable upside, analysts plainly believe Evolus is more favorable than Jushi.

Profitability

This table compares Jushi and Evolus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jushi	-26.90%	N/A	-16.59%
Evolus	-14.39%	N/A	-19.03%

Risk and Volatility

Jushi has a beta of -0.71, suggesting that its stock price is 171% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Insider & Institutional Ownership

21.7% of Jushi shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 23.1% of Jushi shares are owned by insiders. Comparatively, 5.0% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Evolus beats Jushi on 8 of the 13 factors compared between the two stocks.

About Jushi

Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature’s Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.

About Evolus

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.